Skip to main content
Industry News
Long-term use of Rebinyn benefits children with severe hemophilia B

Five-year data from Novo Nordisk's late-stage trial that evaluated long-term treatment using Rebinyn, or nonacog beta pegol, or N9-GP, in previously treated pediatric patients with severe hemophilia B aged 12 years or younger, found the therapy to be safe and effective in treating and preventing spontaneous bleeds. Findings were reported in the journal Thrombosis and Haemostasis.

Full Story: